Billion CAGR (2024-2030): 3.65% Market Segmentation: Reagent Type, Technology, Application, End-users, and Geography ...

The voices, values and lived experience of people living with dementia - and their families - must shape the path forward for ...

The European Medicines Agency (EMA), after initial rejection based on an unfavourable risk-benefit balance, recently recommended approval of lecanemab for treating people with mild cognitive ...

A group of expert neurologists have expressed concerns at the European Commission’s (EC) decision to formally approve the Alzheimer’s drug lecanemab (Leqembi) despite uncertain benefits. Lecanemab, ...

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune ...

Patients are losing out on life-changing drugs for cancer and rare diseases because of Brexit, experts have warned. Treatments could be made available in the EU and US before the UK because of cost ...